GeneDx (NASDAQ:WGS) CFO Kevin Feeley Sells 3,729 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 3,729 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $60.77, for a total value of $226,611.33. Following the transaction, the chief financial officer directly owned 39,954 shares in the company, valued at $2,428,004.58. The trade was a 8.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, June 9th, Kevin Feeley sold 1,266 shares of GeneDx stock. The stock was sold at an average price of $53.77, for a total transaction of $68,072.82.
• On Wednesday, April 29th, Kevin Feeley sold 392 shares of GeneDx stock. The stock was sold at an average price of $65.19, for a total transaction of $25,554.48.

GeneDx Stock Performance

Shares of WGS opened at $59.01 on Friday. The firm has a market capitalization of $1.75 billion, a P/E ratio of -22.02 and a beta of 1.96. GeneDx Holdings Corp. has a 52 week low of $32.21 and a 52 week high of $170.87. The stock has a 50 day moving average price of $54.38 and a two-hundred day moving average price of $86.68. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.95 and a current ratio of 3.09.

GeneDx (NASDAQ:WGS) last posted its earnings results on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). The company had revenue of $102.25 million during the quarter, compared to the consensus estimate of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. During the same quarter in the prior year, the business earned ($0.23) EPS. Equities analysts forecast that GeneDx Holdings Corp. will post -1 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on WGS. Jefferies Financial Group set a $150.00 price objective on GeneDx in a research note on Monday, February 23rd. Wall Street Zen downgraded shares of GeneDx from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Guggenheim reduced their target price on shares of GeneDx from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Canaccord Genuity Group set a $75.00 price target on shares of GeneDx and gave the stock a “buy” rating in a report on Tuesday, May 5th. Finally, Wells Fargo & Company reiterated an “overweight” rating and issued a $75.00 price objective (down from $155.00) on shares of GeneDx in a research note on Tuesday, May 5th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, GeneDx currently has a consensus rating of “Moderate Buy” and a consensus price target of $96.43.

Institutional Investors Weigh In On GeneDx

Several institutional investors have recently added to or reduced their stakes in WGS. Bank of America Corp DE boosted its position in GeneDx by 77.5% during the first quarter. Bank of America Corp DE now owns 234,606 shares of the company’s stock worth $15,066,000 after purchasing an additional 102,456 shares during the period. California State Teachers Retirement System raised its position in shares of GeneDx by 31.2% in the first quarter. California State Teachers Retirement System now owns 25,045 shares of the company’s stock valued at $1,608,000 after purchasing an additional 5,951 shares during the period. Ashford Capital Management Inc. raised its position in shares of GeneDx by 31.9% in the first quarter. Ashford Capital Management Inc. now owns 174,512 shares of the company’s stock valued at $11,207,000 after purchasing an additional 42,186 shares during the period. Quantinno Capital Management LP lifted its stake in shares of GeneDx by 99.2% during the 1st quarter. Quantinno Capital Management LP now owns 3,810 shares of the company’s stock valued at $245,000 after buying an additional 1,897 shares in the last quarter. Finally, First Light Asset Management LLC purchased a new stake in shares of GeneDx during the 1st quarter valued at approximately $15,601,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: GeneDx appointed Mark Gardner as its new company president, a leadership change that could help execution and strategic focus. GeneDx Appoints Mark Gardner as New Company President
• Neutral Sentiment: The company disclosed insider stock sales by CEO Katherine Stueland and CFO Kevin Feeley, but the filings say the shares were sold to meet tax withholding obligations tied to equity vesting. SEC filing for CEO sale SEC filing for CFO sale
• Negative Sentiment: Multiple law firms are promoting a securities class action against GeneDx, alleging investors were misled about the Fabric Genomics acquisition and related performance issues, with a lead-plaintiff deadline of August 3, 2026. Class action lawsuit notice
• Negative Sentiment: The lawsuit coverage highlights the company’s prior earnings disappointment and the large May 2026 stock decline, keeping pressure on investor confidence. Hagens Berman class action article

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.